Token Count
1 VCT = 0.00002 ETH

Vivo Capital is a healthcare focused investment firm formed in 1996 with over $2.2 billion under management. Vivo Capital is currently making investments from its $750M eighth fund into promising private and public healthcare companies in the U.S. and Greater China, from its $635M Opportunity fund into promising public healthcare companies, and from its $100M PANDA fund into promising early-stage innovative healthcare companies.

Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising therapeutic products at all stages in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Beijing, Shanghai and Taipei.

With over 100 years of scientific expertise and operating experience in healthcare, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, facilitate strategic alliances including cross-border partnerships, recruit management, and acquire new products and technologies to accelerate growth. Vivo’s current portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.


Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China. With more than $2.2 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Beijing and Shanghai, China, and Taipei, Taiwan.

At Vivo Capital, we leverage our internal expertise in evaluating data to generate outsized returns for company founders and employees as well as for our investors. Vivo invests primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China. Vivo assists its portfolio companies in both countries in forging cross-border partnerships, enabling the companies to acquire new products and expand the market for their existing products. In addition to making investments in existing companies, Vivo also builds companies from scratch to pursue compelling opportunities together with experienced management teams. Finally, a portion of every Vivo fund is invested directly into public therapeutics companies. Despite its focus on companies with later-stage products, Vivo is willing to work with companies (and their founders) that may not have significant infrastructure. We invest in companies with promising products at all financing stages (Series A to public companies), and work closely with founders and management to complete the development and commercial launch of those products and achieve a successful exit.

Adding Value: Portfolio Synergy, Strategic Partnering and Technology Transfer

After an investment is made, Vivo works closely with the founders and management to build value.

  • We work to ensure the clinical development program is optimized in terms of disease indication, protocol design and regulatory strategy.
  • Intellectual property (IP) is another key component, and Vivo frequently becomes involved in helping guide the IP strategies of its portfolio companies.
  • The final step is to develop a financing strategy with management to ensure the company’s sustainability to an exit.

Vivo’s portfolio encompasses companies in a wide range of therapeutic areas and products. Because the strengths of one portfolio company are often complementary or synergistic with those of another, we encourage communication and potential collaboration among our companies whenever such collaboration makes business sense.

In making investments we emphasize the following criteria:


  • The quality of the company’s underlying technology, including supporting preclinical and clinical data
  • The market potential of the company’s products
  • The strength of the company’s intellectual property
  • The strength of the company’s management team


Frank Kung, Ph.D., M.B.A.

Managing Partner

Dr. Kung is a founding member of Vivo Capital, LLC (formerly BioAsia Investments), a healthcare/biotechnology venture capital management firm in Palo Alto, California. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ: GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He also served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies.

Albert Cha, M.D., Ph.D.

Managing Partner

Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), KalVista Pharmaceuticals (NASDAQ: KALV), and Menlo Therapeutics (NASDAQ: MNLO). He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.

Edgar G. Engleman, M.D.

Managing Partner

Dr. Engleman is a founding member of Vivo Capital, LLC (formerly BioAsia Investments). Dr. Engleman is Professor of Pathology and Medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor of numerous scientific journals and the inventor of multiple patented technologies, Dr. Engleman has authored more than 250 publications in medical and scientific journals and has trained more than 200 graduate students and postdoctoral fellows. He has co-founded a number of biopharmaceutical companies including Cetus Immune, Genelabs, National Medical Audit and Dendreon. He is the lead inventor of the technology underlying Provenge, Dendreon’s cancer vaccine, which was shown to extend life for patients with metastatic prostate cancer with remarkably few side effects. Provenge is the first active immunotherapeutic agent to be approved by the FDA (in 2010). Dr. Engleman currently serves on the boards of several private biotechnology companies. He received his B.A. from Harvard University and his M.D. from Columbia University School of Medicine.

Shan Fu, M.A.

Managing Partner

Shan Fu joined Vivo in 2013 as a Managing Partner, Co-CEO and CEO of China. Before joining Vivo, Mr. Fu worked for Blackstone as Senior Managing Director in the Private Equity group and the Chief Representative of Blackstone’s Beijing Office. Mr. Fu also worked in the Department of Foreign Investment in China’s National Development and Reform Commission (NDRC), the State Economic and Trade Commission of China, the Office of Economic and Trade in State Council of China, and the Office of Production in State Council of China. Mr. Fu received a Bachelor’s and Master’s Degree in History from Peking University in Beijing, China.

Mahendra G. Shah, Ph.D.

Managing Director

Mahendra G. Shah, Ph.D. is a highly successful pharmaceutical entrepreneur and executive who has been at Vivo Capital since March 2010. He is also the founder and executive chairman of Semnur Pharmaceuticals. Dr. Shah currently serves as chairman of the board of Essentialis Therapeutics, board member of Biotie Therapies (NASDAQ: BITI), and a member of the board of trustees of St. John’s University. He is also a board member and charter member of EPPIC and a charter member of TIE. From September 2005 to December 2009, he was the founder, chairman and CEO of NextWave Pharmaceuticals, a pediatric focused specialty pharmaceutical company, which was sold to Pfizer for a total of $700 million in upfront and milestone payments. From 1993 to May 2003 he was the chairman and CEO of First Horizon Pharmaceuticals, a publicly traded specialty pharmaceutical company, where he raised over $200 million and built a highly profitable company before it was sold to Shionogi Pharmaceuticals for $1.4 billion. From 1991 to October 1999, he was vice president of E. J. Financial Enterprises, Inc., which manages a fund that invests in healthcare companies. He previously served on the boards of Unimed Pharmaceuticals (UMED), Introgen Therapeutics (INGN), Inpharmakon, Protomed, Structural Bioinformatics, and Zarix. From 1987 to 1991 he was the senior director of new business development with Fujisawa USA (Astellas). Prior to that time he worked in various scientific and management positions with Schering-Plough and Bristol Myers-Squibb. Dr. Shah received his Ph.D. in industrial pharmacy from St. John’s University and his Bachelor’s and Master’s Degree in Pharmacy from L.M. College of Pharmacy in Gujarat, India.


  • Q1 2018

    Generating the idea.

     Evaluating the market and development potential.

     Market Research.

  • Q2 2018

    Launching the development.

     Expanding the team.

     Developing the company's legal structure.

  • Q3 2018

    Preparing for the ICO.


     Landing page

     Performing Private Sale

     Bounty & AirDrop

  • Q4 2018

    Performing the Pre-sale.

     Performing ICO Main sale.

     Bounty & AirDrop Distribution.

  • Q1 2019

     Exchange Listing Process starts.

     Mobile application testing

     Establishing Representative Office

  • Q2 2019

    Launch the Platform in Full mode

     Mobile application release

  • Q3 2019


     Licensing and entering the Asian market.

  • Q4 2019

     Obtaining the payment licenses.

     Completion of developing the platform core.

White Paper

Investment Info
Accepting ETH
Token Info
Country USA
Hardcap $280,000,000
Softcap $120,000,000
Token VCT
Platform Ethereum
Type ERC20
Token Price 1 VCT = 0.00002 ETH
Token Count 280,000,000
Pre-Sale Start Date 2018-October-01
Pre-Sale End Date 2018-October-15
Crowd Sale Start Date 2018-October-16
Crowd Sale End Date 2018-December-31

Write a review

Note: HTML is not translated!
    Bad           Good
This ICO is being reviewed in detail. This section will be updated soon.

Vivo Capital - Future of Healthcare Innovation(VCT)

Top Raised ICOs - Ending soon

ICOs being viewed at the moment

Bulleon- Join the cryptocurrency revolution
Ending: 31 December
Ending: 25 January
BB Tokens - Marketing and Loyalty Platform(BBT)
Ending: 30 November
GEMERA-Crypto-Token Backed by Colombian Emeralds(GEMA)
Ending: 12 December
Ending: 28 February
TrustedCars Flex - Car Network Image Changing car ownership forever
Ending: 31 October
AvailCom -New-generation property rent of keyless access(AVL)
Ending: 15 February
FRELDO - Smart Contracts for Smart Users (FRECN)
Ending: 31 December
Contentos - The Decentralized Global Content Ecosystem(COS)
Ending: 15 November
Borser - Shares of a holding company in the form of crytocurrency (BOR)
Ending: 31 March
Tresorio HUB - Moving Supercomputing to the Edge(HUB)
Ending: 31 January
Bitbose - The Future Of Crypto Investments
Ending: 30 November
eMusic - Redefining Music Distribution Through Blockchain(EMU)
Ending: 30 April
WankCoin -Token for Adult Entertainment built with Blockchain Tech
Ending: 07 November
Ending: 01 February